Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

HOME
>
論文・技術情報
>
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

アブストラクト	As of 4 April 2021, a total of 169 cases of cerebral venous sinus thrombosis (CVST) and 53 cases of splanchnic vein thrombosis were reported to EudraVigilance among around 34 million people vaccinated in the European Economic Area and United Kingdom with COVID-19 Vaccine AstraZeneca, a chimpanzee adenoviral vector (ChAdOx1) encoding the spike protein antigen of the SARS-CoV-2 virus. The first report of the European Medicines Agency gathering data on 20 million people vaccinated with Vaxzevria(R) in the UK and the EEA concluded that the number of post-vaccination cases with thromboembolic events as a whole reported to EudraVigilance in relation to the number of people vaccinated was lower than the estimated rate of such events in the general population. However, the EMA's Pharmacovigilance Risk Assessment Committee concluded that unusual thromboses with low blood platelets should be listed as very rare side effects of Vaxzevria(R), pointing to a possible link. The same issue was identified with the COVID-19 Vaccine Janssen (Ad26.COV2.S). Currently, there is still a sharp contrast between the clinical or experimental data reported in the literature on COVID-19 and the scarcity of data on the unusual thrombotic events observed after the vaccination with these vaccines. Different hypotheses might support these observations and should trigger further in vitro and ex vivo investigations. Specialized studies were needed to fully understand the potential relationship between vaccination and possible risk factors in order to implement risk minimization strategies.
ジャーナル名	Thrombosis research
投稿日	2021/5/25
投稿者	Douxfils, Jonathan; Favresse, Julien; Dogne, Jean-Michel; Lecompte, Thomas; Susen, Sophie; Cordonnier, Charlotte; Lebreton, Aurelien; Gosselin, Robert; Sie, Pierre; Pernod, Gilles; Gruel, Yves; Nguyen, Philippe; Vayne, Caroline; Mullier, Francois
組織名	University of Namur, Department of Pharmacy, Namur Research for Life Sciences,;Namur Thrombosis and Hemostasis Center, Namur, Belgium; QUALIblood s.a., Namur,;Belgium. Electronic address: jonathan.douxfils@unamur.be.;Namur Thrombosis and Hemostasis Center, Namur, Belgium; Clinique Saint-Luc Bouge,;Department of Laboratory Medicine, Bouge, Belgium.;Namur Thrombosis and Hemostasis Center, Namur, Belgium.;Departements de Medecine, Hopitaux Universitaires de Geneve, service d'angiologie;et d'hemostase et Faculte de Medecine, Geneva Platelet Group (GpG), Universite de;Geneve, Geneva, Switzerland.;Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000;Lille, France.;Univ Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition,;F-59000 Lille, France.;Service d'hematologie biologique, CHU Clermont-Ferrand, Clermont-Ferrand, France.;University of California, Davis Health System, Thrombosis and Hemostasis Center,;Sacramento, United States.;University Paul Sabatier, CHU of Toulouse, Laboratory of Hematology, F-31069;Toulouse, France.;CHU Grenoble Alpes, Department of Vascular Medicine, CNRS/TIMC-IMAG UMR;5525/Themas, Grenoble, France.;University of Tours, EA7501 GICC, CHRU de Tours, Department of Haemostasis,;Tours, France.;Universite de Reims, EA3801, CHU de Reims, France.;CHU UCL Namur, Universite catholique de Louvain, Hematology Laboratory, Namur;Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Yvoir,;Belgium.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/34029848/